We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Conducting Long-Term Observations on Gene Therapy
FDA Issues Guidance on Conducting Long-Term Observations on Gene Therapy
August 23, 2005
The FDA generally will not require long-term follow-up observations of participants in clinical trials of gene transfer technology when the risk of delayed adverse events is low, according to a draft guidance.